Clinical efficacy of first-line treatment of atelizumab plus bevacizumab for recurrent hepato-cellular carcinoma after operation
10.3760/cma.j.cn115610-20211105-00544
- VernacularTitle:阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗肝细胞癌术后复发的临床疗效
- Author:
Min DONG
1
;
Donghao WU
;
Ting JIANG
;
Xiangyuan WU
Author Information
1. 中山大学附属第三医院肿瘤内科，广州 510630
- Keywords:
Liver neoplasms;
Primary;
Immunotherapy;
Targeted therapy;
Ateli-zumab;
Bevacizumab
- From:Chinese Journal of Digestive Surgery
2021;20(S2):5-9
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) has a high recurrence rate after surgical resection. There is little chance for patients with recurrent HCC to receive surgery again, and the main therapy is systemic treatment. However, the efficacy of traditional systemic treatments such as targeted therapy and chemotherapy is limited and the prognosis of patients with advanced HCC is poor. The authors reported a HCC patient who relapsed after surgical resection achieved partial remission with first-line treatment of atelizumab and bevacizumab, according to the latest report of Imbrave150 study. The patient has maintained partial response for more than 1 year, with mild adverse reactions and good efficacy.
